[Organ-preserving treatment of bladder cancer with combined radiochemotherapy: Do patients profit from additional neoadjuvant chemotherapy?].
Diestelhorst
A
A
Dunst
J
J
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001900:Boston; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage*; D017322:Clinical Trials, Phase II as Topic; D004334:Drug Administration Schedule; D005858:Germany; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D018714:Radiotherapy, Adjuvant; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D014747:Vinblastine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D014747:Vinblastine; D002945:Cisplatin; D008727:Methotrexate